Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients’ outcome

References

• Zahid U, Akbar F, Amaraneni A, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12(3):217–226.
   PubMed Web of Science ®Google Scholar
• Stiff P. What is the role of autologous transplant for lymphoma in the current era? Hematology Am Soc Hematol Educ Program. 2015;2015:74–81.
   PubMedGoogle Scholar
• von Tresckow B, Moskowitz CH. Treatment of relapsed and refractory Hodgkin lymphoma. Semin Hematol. 2016;53(3):180–185.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Salles G. Diffuse large B-Cell lymphoma. N Engl J Med. 2021;384(9):842–858.
   PubMed Web of Science ®Google Scholar
• Susanibar-Adaniya S, Barta SK. 2021 Update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617–629.
   PubMed Web of Science ®Google Scholar
• Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132(16):1647–1656.
   PubMed Web of Science ®Google Scholar
• Staton AD, Langston AA. Autologous stem cell transplant: still the standard for fit patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2017;17S:S96–S99.
   PubMedGoogle Scholar
• Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410–2418.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology Am Soc Hematol Educ Program. 2017;2017(1):565–577.
   PubMed Web of Science ®Google Scholar
• Broccoli A, Zinzani PL. Peripheral T-cell lymphoma, not otherwise specified. Blood. 2017;129(9):1103–1112.
   PubMed Web of Science ®Google Scholar
• Schmitz N, de Leval L. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol. 2017;176(6):851–866.
   PubMed Web of Science ®Google Scholar
• Capria S, Barberi W, Perrone S, et al. Reappraising the timing of transplant for indolent non-Hodgkin lymphomas. Expert Rev Hematol. 2016;9(10):951–964.
   PubMed Web of Science ®Google Scholar
• Benekou K, Montoto S. Role of stem cell transplant in lymphoma in the era of new drugs. Curr Opin Oncol. 2017;29(6):455–459.
   PubMed Web of Science ®Google Scholar
• Dahi PB, Lazarus HM, Sauter CS, et al. et al. Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma. Bone Marrow Transplant. 2019;54(7):943–960.
   PubMed Web of Science ®Google Scholar
• Telio D, Fernandes K, Ma C, et al. Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. Leuk Lymphoma. 2012;53(5):836–841.
   PubMed Web of Science ®Google Scholar
• Gupta A, Gokarn A, Rajamanickam D, et al. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: analysis of toxicity, long-term outcome, and prognostic factors. J Can Res Ther. 2018;14(5):926–933.
   PubMed Web of Science ®Google Scholar
• Kondo E. Autologous hematopoietic stem cell transplantation for diffuse large B-Cell lymphoma. J Clin Exp Hematop. 2016;56(2):100–108.
   PubMed Web of Science ®Google Scholar
• Chan FC, Mottok A, Gerrie AS, et al. Prognostic model to predict Post-Autologous Stem-Cell transplantation outcomes in classical Hodgkin lymphoma. J Clin Oncol. 2017;35(32):3722–3733.
   PubMed Web of Science ®Google Scholar
• Bentolila G, Pavlovsky A. Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation. Leuk Lymphoma. 2020;61(7):1548–1554.
   PubMed Web of Science ®Google Scholar
• Shitara K, Matsuo K, Oze I, et al. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol. 2011;68(2):301–307.
   PubMed Web of Science ®Google Scholar
• Shitara K, Matsuo K, Takahari D, et al. Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer. 2009;45(10):1757–1763.
   PubMed Web of Science ®Google Scholar
• Shitara K, Matsuo K, Takahari D, et al. Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. Ann Oncol. 2010;21(12):2403–2409.
   PubMed Web of Science ®Google Scholar
• Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 2005;6(9):669–677.
   PubMed Web of Science ®Google Scholar
• Klimm B, Reineke T, Haverkamp H, et al. Role of hematotoxicity and sex in patients with Hodgkin’s lymphoma: an analysis from the German Hodgkin study group. J Clin Oncol. 2005;23(31):8003–8011.
   PubMed Web of Science ®Google Scholar
• Colloca GA, Venturino A, Guarneri D. Neutrophil count kinetics during the first cycle of chemotherapy predicts the outcome of patients with locally advanced or metastatic pancreatic cancer. Asia Pac J Clin Oncol. 2020;16(4):247–253.
   PubMed Web of Science ®Google Scholar
• Grisariu S, Shapira MY, Or R, et al. Thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan (TECAM) conditioning regimen for autologous stem cell transplantation in lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18(4):272–279.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Vainstein V, Buckley SA, Shukron O, et al. Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia. Leukemia. 2014;28(3):713–716.
   PubMed Web of Science ®Google Scholar
• Holtzman NG, El Chaer F, Baer MR, et al. Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia. Br J Haematol. 2020;188(6):881–887.
   PubMed Web of Science ®Google Scholar
• Vainstein V, Ginosar Y, Shoham M, et al. The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. J Theor Biol. 2005;234(3):311–327.
   PubMed Web of Science ®Google Scholar
• Schirm S, Engel C, Loeffler M, et al. A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment. Theor Biol Med Model. 2014;11(1):24.
   PubMedGoogle Scholar